|
US2803586A
(en)
|
1953-06-29 |
1957-08-20 |
Abbott Lab |
ph control in production of fumagillin
|
|
GB8500209D0
(en)
|
1985-01-04 |
1985-02-13 |
Ceskoslovenska Akademie Ved |
Synthetic polymeric drugs
|
|
SE8702550D0
(sv)
|
1987-06-18 |
1987-06-18 |
Anders Grubb |
Cysteinproteashemmare
|
|
US5166172A
(en)
|
1988-09-01 |
1992-11-24 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
US4997878A
(en)
|
1988-12-29 |
1991-03-05 |
Exxon Research And Engineering Company |
Hydrophobically associating polymers containing dimethyl acrylamide functionality
|
|
US5258453A
(en)
|
1992-01-21 |
1993-11-02 |
University Of Utah |
Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
|
|
GB9320781D0
(en)
|
1993-10-08 |
1993-12-01 |
Erba Carlo Spa |
Polymer-bound camptothecin derivatives
|
|
US20030220233A1
(en)
|
1994-01-24 |
2003-11-27 |
Neorx Corporation |
Radiolabeled annexins
|
|
TW409058B
(en)
|
1996-06-06 |
2000-10-21 |
Daiichi Seiyaku Co |
Method for preparation of a drug complex
|
|
TW527183B
(en)
|
1996-06-06 |
2003-04-11 |
Daiichi Seiyaku Co |
Drug complex
|
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
|
US20020076442A1
(en)
|
1997-09-02 |
2002-06-20 |
Martin Burke |
Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
|
|
DE69824750T2
(de)
|
1997-10-31 |
2005-07-07 |
Children's Medical Center Corp., Boston |
Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
|
|
CO5021134A1
(es)
*
|
1998-05-01 |
2001-03-27 |
Abbott Lab |
Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
|
|
SK16282000A3
(sk)
|
1998-05-01 |
2001-05-10 |
Abbott Laboratories |
Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2
|
|
US6242494B1
(en)
|
1998-05-01 |
2001-06-05 |
Abbott Laboratories |
Substituted β-amino acid inhibitors of methionine aminopeptidase-2
|
|
KR100357542B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
푸마질롤 유도체 및 그 제조방법
|
|
WO1999061061A1
(fr)
|
1998-05-22 |
1999-12-02 |
Daiichi Pharmaceutical Co., Ltd. |
Composites medicamenteux
|
|
US6464850B1
(en)
|
1998-07-31 |
2002-10-15 |
Biowhittaker Molecular Applications, Inc. |
Method for producing hydrophilic monomers and uses thereof
|
|
MXPA01004239A
(es)
|
1998-10-30 |
2002-06-04 |
Daiichi Seiyaku Co |
Compuesto dds y metodo para la medicion del mismo.
|
|
JP4883515B2
(ja)
|
1999-09-08 |
2012-02-22 |
ポリセリックス リミテッド |
均一分子量ポリマー
|
|
US6811788B2
(en)
|
2000-01-19 |
2004-11-02 |
Baofa Yu |
Combinations and methods for treating neoplasms
|
|
US20020002152A1
(en)
|
2000-04-14 |
2002-01-03 |
Craig Richard A. |
Hydrazide and alkoxyamide angiogenesis inhibitors
|
|
US20070161570A1
(en)
|
2000-11-01 |
2007-07-12 |
Praecis Pharmaceuticals, Inc. |
Methionine aminopeptidase-2 inhibitors and methods of use thereof
|
|
US6548477B1
(en)
|
2000-11-01 |
2003-04-15 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
ATE440094T1
(de)
|
2001-09-27 |
2009-09-15 |
Equispharm Co Ltd |
Fumagillolderivate und verfahren zu deren herstellung
|
|
US20040005641A1
(en)
|
2002-02-15 |
2004-01-08 |
Michael Burnet |
Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
|
|
JP4514455B2
(ja)
|
2002-04-11 |
2010-07-28 |
チルドレンズ メディカル センター コーポレーション |
Ｔｎｐ−４７０ポリマー複合体及びその使用
|
|
US20040001801A1
(en)
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
US7030262B2
(en)
|
2002-08-06 |
2006-04-18 |
Abbott Laboratories |
3-Amino-2-hydroxyalkanoic acids and their prodrugs
|
|
US20040116348A1
(en)
|
2002-09-23 |
2004-06-17 |
Ying Chau |
Polymer-linker-drug conjugates for targeted drug delivery
|
|
US7491718B2
(en)
|
2002-10-08 |
2009-02-17 |
Abbott Laboratories |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040228831A1
(en)
|
2003-05-15 |
2004-11-18 |
Belinka Benjamin A. |
Polymeric conjugates for tissue activated drug delivery
|
|
JP4682152B2
(ja)
*
|
2003-12-31 |
2011-05-11 |
ザ・ペン・ステート・リサーチ・ファンデーション |
卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
|
|
US20070287680A1
(en)
|
2004-05-10 |
2007-12-13 |
University Of Utah Research Foundation |
Combined Active and Passive Targeting of Biologically Active Agents
|
|
US7214664B2
(en)
|
2004-12-03 |
2007-05-08 |
The Curators Of The University Of Missouri |
Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
|
|
US20080248030A1
(en)
|
2005-02-02 |
2008-10-09 |
Children's Medical Center Corporation |
Method of Treating Angiogenic Diseases
|
|
US7629315B2
(en)
|
2005-03-09 |
2009-12-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Compositions for blocking the inhibitory effect of human CRP on human leptin
|
|
WO2006124711A1
(en)
|
2005-05-16 |
2006-11-23 |
The Board Of Trustees Of The University Of Illinois |
Composition and method for providing localized delivery of a therapeutic agent
|
|
JP2010531896A
(ja)
|
2007-06-26 |
2010-09-30 |
チルドレンズ メディカル センター コーポレーション |
治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
|
|
WO2009036108A1
(en)
|
2007-09-13 |
2009-03-19 |
Children's Medical Center Corporation |
Methods and compositions for inhibiting vascular leakage
|
|
US20090104210A1
(en)
|
2007-10-17 |
2009-04-23 |
Tota Michael R |
Peptide compounds for treating obesity and insulin resistance
|
|
AU2008321382A1
(en)
*
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
|
|
WO2009064738A2
(en)
*
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
|
|
BRPI0820229A2
(pt)
|
2007-11-28 |
2017-05-09 |
A Stevenson Cheri |
conjugados de análogos de fumagilina biodegradáveis biocompatíveis
|
|
AU2008335469A1
(en)
|
2007-12-13 |
2009-06-18 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
EP2307032A4
(en)
|
2008-05-22 |
2014-08-20 |
Univ Ramot |
NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS
|
|
DE102008027574A1
(de)
|
2008-06-10 |
2009-12-17 |
Merck Patent Gmbh |
Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
|
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US8642650B2
(en)
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
TWI373345B
(en)
|
2009-02-19 |
2012-10-01 |
Academia Sinica |
Breast cancer-targeting peptides and use thereof
|
|
EP2493497A4
(en)
|
2009-11-01 |
2013-07-24 |
Brigham & Womens Hospital |
NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
|
|
BR112012016793A2
(pt)
*
|
2010-01-08 |
2018-07-31 |
Zafgen Corp |
compostos tipo fumagilol e métodos de fazer e usar os mesmos
|
|
WO2011127304A2
(en)
|
2010-04-07 |
2011-10-13 |
Zafgen Corporation |
Methods of treating an overweight subject
|
|
US20130137831A1
(en)
|
2010-05-25 |
2013-05-30 |
John S. Petersen |
Optimized drug conjugates
|
|
WO2011150022A2
(en)
*
|
2010-05-25 |
2011-12-01 |
Syndevrx, Inc. |
Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
|
|
US9895449B2
(en)
|
2010-05-25 |
2018-02-20 |
Syndevrx, Inc. |
Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
|
|
PH12013500934A1
(en)
|
2010-11-09 |
2022-10-24 |
Zafgen Inc |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
|
EP2786755A3
(en)
|
2010-11-12 |
2014-10-29 |
Pharma Mar S.A. |
Combination therapy with an antitumor alkaloid
|
|
AU2012225531B2
(en)
|
2011-03-08 |
2017-03-30 |
Zafgen, Inc |
Oxaspiro (2.5) octane derivatives and analogs
|
|
EP3574922B1
(en)
*
|
2013-04-10 |
2021-09-15 |
Syndevrx, Inc. |
Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity
|
|
EP4772247A2
(en)
|
2013-08-14 |
2026-07-08 |
Novartis AG |
Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
|
|
KR102849342B1
(ko)
|
2015-12-10 |
2025-08-21 |
신데브알엑스, 인크. |
푸마길롤 유도체 및 그의 다형체
|
|
AU2017206718B2
(en)
*
|
2016-01-11 |
2021-09-30 |
Syndevrx, Inc. |
Treatment for tumors driven by metabolic dysfunction
|
|
MX2019001467A
(es)
|
2016-08-03 |
2019-10-02 |
Remd Biotherapeutics Inc |
Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
|
|
US11612577B2
(en)
|
2018-10-26 |
2023-03-28 |
Syndevrx, Inc. |
Biomarkers of METAP2 inhibitors and applications thereof
|